Phase/Process	Key requirements	Researcher (Please tick \/)	Secretariat MREC (Please tick \/)
Pre-clinical studies     (investigators must show their own data and not from other laboratories)	Approval letter from animal ethics committee is recommended		
	institution requiring OLF compliance		
	Evidence that the pre-clinical studies was subjected to rigorous and independent peer review and regulatory oversight		
	Safety data in small animals		
	Safety data in large animals		
	Comprehensive toxicology data in small animals (including contamination, acute infusional toxicity, deleterious immune responses, unexpected behavior of the cellular product, and tumorigenesis)		
	Comprehensive toxicology data in large animals (including risks of contamination, acute infusional toxicity, deleterious immune responses, unexpected behavior of the cellular product, and tumorigenesis)		
	Proof of principle of the desired effect (that the cells have repaired the damage/disease)     unequivocal efficacy data		
	Show biological distribution data		
	Show evidence of physiologic integration and long-lived tissue reconstitution		
	Show that differentiation (either <i>in vitro</i> before transplantation or <i>in vivo</i> after transplantation) occur only along the desired lineages		
	Design based on clinical expectations		
	Mechanistic studies to show biology (done by the group)		
	GLP compliant		

Phase/Process	Key requirements	Researcher (Please tick \/)	Secretariat MREC (Please tick \/)
	Evidence that the pre-clinical data has been submitted to the NPCB		
2. Phase I trials	Comprehensive pre-clinical studies have been done and data showed safety and efficacy in animals (performed by the group) is recommended		
	Procedures on how the cells be tracked in terms of homing to the target area, viability and longevity of the cells		
	Procedures on how the safety be monitored		
	Procedures to assess risks of tumorigenicity by an independent body must be implemented		
	Procedures to assess short, medium and long term side effects		
	GCP compliance		
3. Phase II trials	Data from Phase I trials (performed by the group themselves and if the trial is not performed by the group, explain why the data should be used for this trial)		
	Procedures on how the cells be tracked in terms of homing to the target area and viability of the cells		
	Optimisation of dose, route, regimen, patient population, endpoints, and controlled		
	Procedures on how the safety be monitored		
	Independent data safety monitoring board		
	Plan to assess short, medium and long term side effects      CCR compliance		
	GCP compliance		

4. Phase III trials	Data from Phase II trials (performed by the group themselves)	
	Design to show safety and efficacy	
	Independent data safety monitoring board	
	GCP compliance	
	Conduct 'randomised' control	
5. Cell processing and manufacturing	Evidence by a letter of conformance for GMP compliance and issued by relevant authority	
	Show evidence of relevant processes:     Standard operating procedures, quality standards, environmental control, equipment qualification, analytical methods, audits, staff training, etc.	
	Cell processing and manufacture of any product must be conducted under scrupulous, expert, and independent review	
	Demonstrate that the product is safe, pure and potent	
6. Product registration	Show that the product has been registered with the National Pharmaceutical Control Bureau before use in human trials	
	License for clinical trial has been obtained	
7. Cell characterization ( pre-requisite to clinical trials)	History of the cells in the stem cell or cell-based product	
	Biological characterisation of cell type	
	Demonstration of purity	
	Demonstration of potency (e.g. cells produce insulin in a physiological manner)	
	Manufacturing standards and independent certification, where relevant	
	Evidence that cells are free from contamination	

	Evidence of viability and longevity of cells after transplantation (to determine the likely duration of the therapeutic effect)	
	Evidence that cells will home into the area of damage or repair	
	Evidence of genomic stability during culture	
8. Investigators and researchers	• Is the Principal Investigator trained in cell transplantation? (Show evidence of credentialing)	
	Are other investigators trained in cell transplantation? (Show evidence of credentialing)	
	Qualifications of scientists and researchers	
	Registration with National Medical Research Register, Ministry of Health (MOH)	
9. Centres performing therapy (Information for patients)	Registration with PHCFS Act, Ministry of Health	
	Informing subjects about the human embryonic cell source, if applicable	
	The unique risks; and disclose honestly that the treatment have not been tried before	
	Utmost clarity on the potential benefit	
	Disclosing financial and non-financial conflicts of interest	
	Provide monitoring patients long term	
	Providing a clear, timely, and effective plan for adverse event reporting	